Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

NCT03410615 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

129

Enrollment

NETWORK

Sponsor class

Conditions

Oropharyngeal Squamous Cell Carcinoma

Interventions

RADIATION: Radiation
DRUG: Cisplatin
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]